Because of the persistent donor shortage, several stem cell based therapies for liver disease have been proposed; namely, extracorporeal bioartificial liver devices, cell transplantation, and tissue-engineered constructs. Despite their differences, these therapies share a requirement for adequate cell supply and stability of liver-specific functions. Although some extracorporeal cell-based support devices are already in clinical trials, the efficacy of engineered cell therapies in the management of liver disease can be improved further by incorporating strategies for maximizing stem cell derived hepatocyte function. Current cell-based approaches will rely on a variety of cell sources, whether primary or stem cells, which will ultimately interact with the microenvironment en route to providing key liverspecific functions. To apply such strategies, lessons must be drawn from classic liver biology as well as the experience of transplant medicine in supporting liver failure patients.
